Influence of body temperature on indinavir crystallization under loop of Henle conditions

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 1, 2007, Pages 114-117

  Salahuddin, Saima ^a,b   Kok, Dik J ^a   Buchholz, Noor N P ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Dosages; Drug kinetics; In vitro experiments; Protease inhibitors

Indexed keywords

BUFFER; INDINAVIR; SODIUM HYDROXIDE;

ARTICLE; BODY TEMPERATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HENLE LOOP; IN VITRO STUDY; IONIC STRENGTH; KIDNEY PROXIMAL TUBULE; PRECIPITATION; ROOM TEMPERATURE; TEMPERATURE MEASUREMENT; TEMPERATURE SENSITIVITY; URINE PH; UROLITHIASIS;

ANTI-HIV AGENTS; BODY TEMPERATURE; CRYSTALLIZATION; HUMANS; HYDROGEN-ION CONCENTRATION; INDINAVIR; KIDNEY CALCULI; LOOP OF HENLE;

EID: 33845864690     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl436     Document Type: Article

References (10)

1. Hug B, Naef M. Treatment for human immunodeficiency virus with indinavir may cause relevant urological side effects, effectively treatable by rehydration. BJU Int 1999; 84: 610-4.
2. Dieleman JP, Salahuddin S, Hsu YS et al. Indinavir crystallization around the loop of Henle: Experimental evidence. J Acquir Immune Defic Syndr 2001; 28: 9-13.
3. Kok DJ. Crystallization and stone formation inside the nephron. Scanning Microsc 1996; 10: 471-86.
4. Reiter WJ, Schoen-Pernerstorfer H, Dorfinger K et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999; 161: 1082-4.
5. Wasmuth JC, la Porte CJ, Schneider K et al. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir Ther 2004; 9: 213-20.
6. Daudon M, Estepa L, Viard JP et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349: 1294-5.
7. Dieleman JP, Gyssens IC, van der Ende ME et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
8. Yeh KC, Stone JA, Carides AD et al. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: Study design and model-independent data analysis. J Pharm Sci 1999; 88: 568-73.
9. Burger D, Boyd M, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51: 1231-8.
10. Acosta EP, Henry K, Baken L et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708-12.